Skip to main content

Table 1 Fasting PCSK9 and lipid levels pre- and post-fibrate treatment

From: Plasma PCSK9 levels are significantly modified by statins and fibrates in humans

  Baseline Treatment % Change
PCSK9 (μg/mL) 6.04 ± 1.10 6.90 ± 1.38* 17.01 ± 29.5
Total cholesterol 6.22 ± 0.73 5.50 ± 0.88** -11.3 ± 11.6
Triglycerides 3.27 ± 0.59 1.85 ± 0.80*** -43.6 ± 22.8
HDL cholesterol 0.86 ± 0.13 1.00 ± 0.21** 15.7 ± 18.4
LDL cholesterol 3.85 ± 0.65 3.65 ± 0.71 -4.22 ± 17.6
TC/HDLC Ratio 7.35 ± 1.22 5.79 ± 1.68*** -22.0 ± 13.5
  1. Significance comparing baseline and treatment by Wilcoxon's signed rank test (n = 19). Values expressed as μmol/L except where indicated.
  2. *p < 0.05, **p < 0.001, ***p < 0.0001